Press Releases

Sanofi-aventis and Ascendis Pharma (Ascendis) announced a global licensing and patent transfer agreement on Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology, which allows for a drug compound to be released in the body in a precise, time-controlled fashion,...

Bristol-Myers Squibb Company and Pfizer Inc.announced that the ADVANCE-3 study results, published in The New England Journal of Medicine, showed apixaban was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients...

Novartis has received approval from Japan's Ministry of Health, Labour and Welfare to offer Tasigna® (nilotinib) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The...

Eli Lilly and Company announced that it has completed the acquisition of Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases. The transaction, first announced on...

Merck KGaA announced today that it has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which its division Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block...

Development of a vaccine to prevent the malaria parasite from entering the human liver is the goal of a new collaboration announced by global leaders in malaria research and vaccine development. The PATH Malaria Vaccine Initiative (MVI), Merck (known...

New data to be presented show that afatinib (BIBW 2992) leads to a significant four-fold extension (4.4 months vs. 1 month for placebo) in progression-free survival, - the time before a tumour starts to grow again- , for lung...